口服降糖药二肽基肽酶Ⅳ抑制剂的研究进展

The Research Progress in Oral Medications Dipeptidyl Peptidase-4 Inhibitors

随着人们生活水平的不断提高,生活习惯的改变,糖尿病目前已经成为危害人类健康的主要疾病之一。据国际糖尿病联盟(IDF)统计,糖尿病患者人数呈逐年增长趋势,并趋于年轻化。DPP-Ⅳ抑制剂(二肽基肽酶Ⅳ抑剂,dipeptidyl peptidase-4 inhibitors)作为一种新型的口服降糖药,已经开始应用于临床,无论是单独还是联合用药,都表现出可靠的有效性和安全性,它们能够有效降低空腹血糖、Hb A1c水平,并具有不影响胃排空、较少发生低血糖和体重增加等优点,为糖尿病患者提供了新的治疗途径。主要介绍了目前已上市的五种DPP-Ⅳ抑制剂及其药动学特点,着重介绍了DPP-Ⅳ抑制剂作为一类新型降糖药物,单独治疗及联合治疗与其他类别降糖药相比降糖效果如何。

With the continuous improvement of people＇s living standards and changes in lifestyle, diabetes has become one of the major diseases that threaten human health. According to the International Diabetes Federation （IDF） statistics, the number of patients with diabetes increases year by year, and the age tends to be younger. As novel oral hypoglycemic agents, Dipeptidyl peptidase-4 （DPP-IV） inhibitors have been widely used in clinical and demonstrated effective and safe, either alone or in combination with other hypoglyeemics. They are able to reduce fasting blood glucose and HbAIc levels effeetively while do not affect gastrie emptying and with less probability of hypoglycemia and weight gain, which provide for diabetics a new therapeutic approach. This paper describes the current five DPP-1V inhibitors and their pharmaeokinetie characteristics listed, highlighting the effect of DPP-IV inhibitors which as a new class of antidiabetic drugs comparing between other classes of antidiabetie drug with monotberapy and combination therapy.